NOVO-NORDISK B ADR/1DK 10 revenue breakdown overview

NOVO-NORDISK B ADR/1DK 10 revenue for the last year amounted to 30.67 B EUR, the most of which — 28.28 B EUR — came from its highest performing source at the moment, Diabetes and Obesity Care, the year earlier bringing 20.65 B EUR. The greatest contribution to the revenue figure was made by United States — last year it brought NOVO-NORDISK B ADR/1DK 10 16.77 B EUR, and the year before that — 11.17 B EUR.